Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (a foreign private issuer) for the month of February 2017, with a filing date of February 6, 2017. The registrant is headquartered in Kfar Saba, Israel, and files annual reports on Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific legal proceeding rather than financial performance.
Material Changes and Events
- Interim Relief Granted: On February 5, 2017, the District Court of Tel Aviv granted the Company's request for interim relief.
- Stock Option Extension: The court extended the expiration date of the Company's Series-1 Stock Options from the original date of February 15, 2017, to February 25, 2017.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or general business risks. The primary contingency addressed is the legal status of the Series-1 Stock Options, which has been temporarily resolved via court order.
Key Facts for Investor Verification
- Verify the final expiration date of Series-1 Stock Options is now February 25, 2017.
- Confirm the status of the Series-1 Stock Options after the interim relief period concludes.
- Note that this filing is incorporated by reference into the Company's Registration Statement on Form S-8 (Registration No. 333-214817).